文献速递颈动脉与弓上血管

CMS决策后tfCAS、TCAR与CEA在标准和高危患者中的比较结局

Comparative outcomes of transfemoral carotid artery stenting versus carotid endarterectomy versus transcarotid artery revascularization in standard- and high-risk patients since the CMS decision in October 2023 using the VQI.
PubMed 文献 · J Vasc Surg · 2025-08-22

标准风险患者中tfCAS总体及无症状和症状亚组卒中/死亡风险高于CEA,也高于TCAR。高危患者中TCAR卒中/死亡风险低于CEA和tfCAS。

要点

  • 标准风险患者中tfCAS围术期卒中/死亡风险高于CEA。
  • 高危患者中TCAR围术期卒中/死亡风险低于CEA和tfCAS。
  • 标准风险症状患者加权后tfCAS和TCAR与CEA无显著差异。

核心结论

  • 标准风险患者中tfCAS总体及无症状和症状亚组围术期卒中/死亡风险高于CEA。
  • 标准风险患者中tfCAS总体围术期卒中/死亡风险高于TCAR。
  • 高危患者中TCAR围术期卒中/死亡风险低于CEA和tfCAS。

研究设计与样本

  • 按CMS标准分为标准风险和高危,并按症状状态分层。
  • 采用逆概率治疗加权调整高危患者和标准风险症状患者的混杂因素。

主要发现

  • 标准风险无症状患者围术期卒中/死亡率tfCAS 1.6%、TCAR 1.2%、CEA 1.0%(P = .01)。
  • 标准风险症状患者围术期卒中/死亡率tfCAS 2.9%、TCAR 1.9%、CEA 1.7%(P = .01)。
  • tfCAS与CEA比较总体卒中/死亡OR 1.89(1.43, 2.48),P < .01。
  • tfCAS与TCAR比较总体卒中/死亡OR 1.59(1.15, 2.18),P < .01。
  • 高危患者中TCAR与CEA比较卒中/死亡aOR 0.75(0.59, 0.94),P = .01;tfCAS与TCAR比较aOR 1.57(1.25, 1.98),P < .01。

临床怎么用

  • 标准风险患者选择血运重建方式时需权衡tfCAS的卒中/死亡风险。
  • 高危患者中TCAR可能提供更优的围术期安全性。
  • 标准风险症状患者加权后tfCAS和TCAR与CEA无显著差异,需个体化决策。

局限性

  • 回顾性分析,存在选择偏倚可能。
  • 仅纳入VQI数据库,可能存在登记偏倚。
  • 未报告长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In October 2023, Centers for Medicare & Medicaid Services (CMS) approved transfemoral carotid artery stenting (tfCAS) for standard-risk patients. Thus, we sought to compare outcomes among tfCAS, transcarotid artery revascularization (TCAR), and carotid endarterectomy (CEA) in standard-risk and high-risk patients. METHODS: All carotid revascularization procedures in the Vascular Quality Initiative after the CMS decision (October 2023-March 2025) were analyzed. Patients were classified as standard-risk or high-risk per CMS criteria and stratified by symptom status. The primary outcome was perioperative stroke/death. Inverse probability of treatment weighting was performed to mitigate selection bias in high-risk patients and included demographics, comorbidities, physician volume, and operative characteristics. Inverse probability of treatment weighting was also applied to symptomatic standard-risk patients to account for the large proportion of tfCAS cases performed outside of Society for Vascular Surgery guidelines. RESULTS: Overall, 57,843 patients underwent revascularization (9123 tfCAS, 21,814 TCAR, and 26,906 CEA). Before weighting, tfCAS patients were more often symptomatic (standard-risk: tfCAS: 45% vs TCAR: 25% vs CEA: 31%, P < .01; high-risk: 35% vs 24% vs 28%, P < .01), more frequently had a modified Rankin score of 4 or 5 (standard-risk: 7.7% vs 2.4% vs 1.7%; high-risk: 6.6% vs 2.6% vs 2.4%, P < .01), and more frequently underwent urgent or emergent surgery (standard-risk: 33% vs 11% vs 16%, high-risk: 28% vs 12% vs 17%, P < .01). Standard-risk asymptomatic patients undergoing tfCAS had the highest rates of perioperative stroke/death (1.6% vs 1.2% vs 1.0%, P = .01), as did symptomatic patients (2.9% vs 1.9% vs 1.7%, P = .01). tfCAS was associated with higher overall odds of stroke/death compared with CEA (odds ratio [OR]: 1.89 [1.43, 2.48], P < .01) and TCAR (OR: 1.59 [1.15, 2.18], P < .01). Compared with CEA, tfCAS was associated with higher odds of stroke/death in both asymptomatic (OR: 1.71 [1.12, 2.55], P = .01) and symptomatic patients (adjusted OR [aOR]: 1.78 [1.21, 2.56], P < .01). After weighting, there were no significant differences in perioperative stroke/death overall for either tfCAS or TCAR compared with CEA in standard-risk symptomatic patients. In high-risk patients, TCAR was associated with lower odds of perioperative stroke/death overall compared with CEA (1.5% vs 2.1%, aOR: 0.75 [0.59, 0.94], P = .01), whereas tfCAS had higher odds of stroke/death compared with TCAR (1.5% vs 2.4%, aOR: 1.57 [1.25, 1.98], P < .01). CONCLUSIONS: In this retrospective analysis, there were higher odds of perioperative stroke/death when comparing tfCAS with CEA overall and among asymptomatic and symptomatic standard-risk patients, as well as overall compared with TCAR. In high-risk patients, TCAR performed better with lower odds of stroke/death compared with both CEA and tfCAS.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Caron E, Van Galen I, Darling JD, et al. Comparative outcomes of transfemoral carotid artery stenting versus carotid endarterectomy versus transcarotid artery revascularization in standard- and high-risk patients since the CMS decision in October 2023 using the VQI. J Vasc Surg. 2025. PMID: 40850611. doi:10.1016/j.jvs.2025.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。